Viz HCM

Viz HCM is an AI-powered software that analyzes 12-lead ECGs using a convolutional neural network to identify patterns suggestive of hypertrophic cardiomyopathy in adult patients. Its purpose is to provide real-time alerts to clinicians, facilitating earlier detection and referral for specialized evaluation, thereby aiming to improve outcomes for a frequently underdiagnosed condition.

Viz HCM is an artificial intelligence software specifically developed to assist in the early detection of hypertrophic cardiomyopathy (HCM). It integrates into existing clinical ECG workflows, automatically analyzing 12-lead electrocardiograms from adult patients. When the software identifies ECG patterns indicative of HCM, it triggers real-time alerts through the Viz.ai platform, aiming to facilitate timely follow-up actions like echocardiography or genetic testing. The core of Viz HCM's diagnostic capability lies in a convolutional neural network (CNN) trained on an extensive dataset of thousands of ECGs. This AI model is engineered to discern specific voltage abnormalities and repolarization changes that are characteristic markers of HCM. The system underwent retrospective validation, successfully meeting performance endpoints, and is designed to help clinicians identify cases of cardiomyopathy that might otherwise be overlooked, thereby accelerating referrals to specialized care.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific ECG features, beyond general voltage abnormalities and repolarization changes, does the convolutional neural network prioritize for HCM detection?; How does the performance of Viz HCM compare to experienced cardiologists in interpreting ECGs for suspected HCM, particularly in diverse patient populations?; What is the positive predictive value and negative predictive value of Viz HCM in a real-world clinical setting, and how does this impact the rate of unnecessary follow-up investigations?; Can the Viz HCM algorithm differentiate between HCM and other cardiac conditions that may present with similar ECG abnormalities, such as athlete's heart or hypertensive heart disease?; What are the long-term clinical outcomes for patients identified by Viz HCM compared to those diagnosed through traditional pathways, particularly concerning early intervention efficacy?